期刊文献+

神经节苷脂联合普拉克索治疗血管性帕金森临床观察 被引量:20

Clinical observation of ganglioside combined with pramipexole on vascular Parkinson's
下载PDF
导出
摘要 目的观察神经节苷脂联合普拉克索治疗血管性帕金森的临床疗效。方法 94例血管性帕金森患者随机分为对照组及观察组,每组47例。两组基础治疗相同,观察组加用普拉克索0.25 mg/次,3次/d,神经节苷脂40 mg,1次/d;对照组加用美多巴,开始剂量每次1/4片,每日3次,逐渐加量,每日最多不超过5片。治疗12周后,比较两组治疗前后UPDRS评分和总有效率。结果观察组的UPDRS评分与对照组比较差异有统计学意义(P<0.05),总有效率也明显优于对照组(P<0.05)。结论神经节苷脂联合普拉克索可有效治疗血管帕金森病。 Objective To observe the clinical efficacy of ganglioside combined with pramipexole on vascular Parkinsonism. Methods 94 cases of vascular parkinsonism patients were randomly divided into control group and ob-servation group ,47 cases in each group. Observation group was given pramipexole 0.25 mg, three times a day, ganglio-side 40 mg + 250 mL 0. 9% saline injection, once daily. Control group was given madopa, starting dose 1/4 tablets, 3 times daily, the volume was gradually increased (not more than 5 tablets daily). After 12 weeks, the UPDRS score and total efficiency of the two groups were compared. Results There were significant differences in the UPDRS score and the total efficiency between the two groups ( P 〈 0. 05 ). Conclusion Ganglioside combined pramipexole is effective to treat vascular parkinsonism.
作者 黄芳
机构地区 湖北省新华医院
出处 《实用药物与临床》 CAS 2013年第6期538-539,共2页 Practical Pharmacy and Clinical Remedies
关键词 血管性帕金森病 普拉克索 神经节苷脂 Vascular parkinsonism Pramipexole Ganglioside
  • 相关文献

参考文献5

二级参考文献16

  • 1王新德.帕金森病及帕金森综合征的诊断标准和鉴别诊断[J].中华神经精神科杂志,1985,18(4):256-256.
  • 2Le W. D. , Jankovic J. Are dopamine receptor agonists neuroprotectire in Parkinson' s disease. Drugs Aging, 2001,18(6) : 389-396.
  • 3Schapira A. H. Neuroprotection and dopamine agonists. Neurology, 2002, 58(4 Suppl 1 ) :S9-S18.
  • 4Le W. D. , Jankovic J. , Xie W. , et al. Antioxidant property opramipexole independent of dopamine receptor activation in neuroprotection. J Neural Transm, 2000, 107(10) :1165-1173.
  • 5Winikates J, Jankovie J. Clinical correlates of vascular parkinsonism.Arch Neurol, 1999, 56(1): 98- 102.
  • 6Richards M, chaudhuri KR. Parkinson's disease in populations of African origin:a revicws. Neuroepidemiology, 1996, 15(4): 214-221.
  • 7Zhuchenko TD, Vein AM, GolubevVL, et al. Vascular parkinsonism.Zh Newol Paikhiatr Im S S Korsakova, 1998, 98(4): 62-65.
  • 8Yamanouchi H, Nagura H. Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopatholgic study. Stroke,1997, 28(5): 965 - 969.
  • 9Tohgi H, Abe T, Sahelci M, et al. Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson' s diseases patients. J Neural Transm, 1997, 104(4 - 5): 441 - 449.
  • 10Abe K, Terakawa H, Takanashi M, et al. Proton magnetic resonance spectroscopy of patients with parkinsonism. Brain Res Bull, 2000, 52(6): 589 - 595.

共引文献20

同被引文献134

引证文献20

二级引证文献112

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部